Beijing Erai Therapeutics has identified aminoheteroaryl compounds acting as mitochondrial brown fat uncoupling protein 1 (UCP1) activators reported to be useful for the treatment of nonalcoholic steatohepatitis (NASH), diabetes and obesity.
The University of Texas System has described new nimbolide derivatives reported to be useful for the treatment of cancer, especially poly [ADP-ribose] polymerase (PARP)-resistant cancer.
Design Therapeutics has discovered conjugates consisting of a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence linked to a protein-binding moiety through an oligomeric backbone linker reported to be useful for the treatment of Friedreich ataxia.
Rhizen Pharmaceuticals and Incozen Therapeutics have synthesized new cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, Alzheimer's disease, pulmonary fibrosis, inflammatory disorders, psoriasis and rheumatoid arthritis, among other disorders.
Jinan University and Guangzhou Lixin Pharmaceuticals have presented new 2-aminopyrimidine compounds acting as tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of cancer and inflammation.
The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have divulged thienyl and cycloalkyl aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatment of cancer and fibrosis.
RSS